This innovative strategy is fostering clinical trials focused on ALS patients with specific genetic aberrations, including SOD1 mutations [16], C9orf72 hexanucleotide repeat expansions [17], ATXN2 trinucleotide expansions [18], and FUS mutations [19]. This evidence concerns the gene ATXN2 and amyotrophic lateral sclerosis.